These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364 [TBL] [Abstract][Full Text] [Related]
3. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow. Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027 [TBL] [Abstract][Full Text] [Related]
4. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Huang YW; Richardson JA; Tong AW; Zhang BQ; Stone MJ; Vitetta ES Cancer Res; 1993 Mar; 53(6):1392-6. PubMed ID: 8443818 [TBL] [Abstract][Full Text] [Related]
5. Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system. Huang SY; Tien HF; Su FH; Hsu SM Am J Pathol; 2004 Feb; 164(2):747-56. PubMed ID: 14742278 [TBL] [Abstract][Full Text] [Related]
6. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Yata K; Yaccoby S Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929 [TBL] [Abstract][Full Text] [Related]
7. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. Hjorth-Hansen H; Seifert MF; Börset M; Aarset H; Ostlie A; Sundan A; Waage A J Bone Miner Res; 1999 Feb; 14(2):256-63. PubMed ID: 9933480 [TBL] [Abstract][Full Text] [Related]
8. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice. Tong AW; Huang YW; Zhang BQ; Netto G; Vitetta ES; Stone MJ Anticancer Res; 1993; 13(3):593-7. PubMed ID: 8391243 [TBL] [Abstract][Full Text] [Related]
9. Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue. Goldstein H; Pettoello-Mantovani M; Anderson CM; Cordelier P; Pomerantz RJ; Strayer DS J Infect Dis; 2002 May; 185(10):1425-30. PubMed ID: 11992277 [TBL] [Abstract][Full Text] [Related]
10. The development of a model for the homing of multiple myeloma cells to human bone marrow. Urashima M; Chen BP; Chen S; Pinkus GS; Bronson RT; Dedera DA; Hoshi Y; Teoh G; Ogata A; Treon SP; Chauhan D; Anderson KC Blood; 1997 Jul; 90(2):754-65. PubMed ID: 9226176 [TBL] [Abstract][Full Text] [Related]
11. An in vivo model of human multiple myeloma bone disease. Alsina M; Boyce BF; Mundy GR; Roodman GD Stem Cells; 1995 Aug; 13 Suppl 2():48-50. PubMed ID: 8520511 [TBL] [Abstract][Full Text] [Related]
12. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Mitsiades CS; Mitsiades NS; Bronson RT; Chauhan D; Munshi N; Treon SP; Maxwell CA; Pilarski L; Hideshima T; Hoffman RM; Anderson KC Cancer Res; 2003 Oct; 63(20):6689-96. PubMed ID: 14583463 [TBL] [Abstract][Full Text] [Related]
13. The SCID-hu mouse: a small animal model for the analysis of human hematolymphoid differentiation and function. McCune JM Bone Marrow Transplant; 1992; 9 Suppl 1():74-6. PubMed ID: 1354528 [No Abstract] [Full Text] [Related]
14. The use of animal models in multiple myeloma. Libouban H Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798 [TBL] [Abstract][Full Text] [Related]
15. Mouse plasmacytoma: an experimental model of human multiple myeloma. Gadó K; Silva S; Pálóczi K; Domján G; Falus A Haematologica; 2001 Mar; 86(3):227-36. PubMed ID: 11255268 [TBL] [Abstract][Full Text] [Related]
16. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. Campbell RA; Manyak SJ; Yang HH; Sjak-Shie NN; Chen H; Gui D; Popoviciu L; Wang C; Gordon M; Pang S; Bonavida B; Said J; Berenson JR Int J Oncol; 2006 Jun; 28(6):1409-17. PubMed ID: 16685443 [TBL] [Abstract][Full Text] [Related]
17. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Wang M; Zhang L; Han X; Yang J; Qian J; Hong S; Lin P; Shi Y; Romaguera J; Kwak LW; Yi Q Clin Cancer Res; 2008 Apr; 14(7):2154-60. PubMed ID: 18381957 [TBL] [Abstract][Full Text] [Related]
18. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Yaccoby S; Barlogie B; Epstein J Blood; 1998 Oct; 92(8):2908-13. PubMed ID: 9763577 [TBL] [Abstract][Full Text] [Related]
19. Autoimmunity. Insights provided by the SCID mouse model. Jorgensen C; Bologna C; Sany J Rev Rhum Engl Ed; 1995; 62(7-8):519-24. PubMed ID: 8574616 [TBL] [Abstract][Full Text] [Related]
20. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Tassone P; Neri P; Carrasco DR; Burger R; Goldmacher VS; Fram R; Munshi V; Shammas MA; Catley L; Jacob GS; Venuta S; Anderson KC; Munshi NC Blood; 2005 Jul; 106(2):713-6. PubMed ID: 15817674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]